Align Technology (ALGN) Receiving Somewhat Favorable News Coverage, Study Shows
News articles about Align Technology (NASDAQ:ALGN) have trended somewhat positive this week, Accern reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Align Technology earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 46.6164123978081 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Luminex (LMNX) at 52-Week High: What's Driving the Stock? (finance.yahoo.com)
- Here's Why You Should Invest in Masimo (MASI) Right Now (finance.yahoo.com)
- Here’s Why You Should Invest in Align Technology (ALGN) Now (finance.yahoo.com)
- Here's Why You Should Invest in Align Technology (ALGN) Now (finance.yahoo.com)
- Lookout for Volatility – Align Technology, Inc., (NASDAQ: ALGN) – Stock Watch (stocksnewstimes.com)
A number of brokerages have recently issued reports on ALGN. Stifel Nicolaus reaffirmed a “buy” rating and issued a $225.00 price target (up from $205.00) on shares of Align Technology in a research note on Thursday, October 19th. Northcoast Research reaffirmed a “buy” rating and issued a $230.00 price target (up from $200.00) on shares of Align Technology in a research note on Tuesday, October 10th. Credit Suisse Group reaffirmed a “positive” rating and issued a $261.00 price target (up from $209.00) on shares of Align Technology in a research note on Thursday, November 9th. Bank of America Corporation raised Align Technology from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $175.00 to $193.00 in a research note on Friday, July 28th. Finally, Zacks Investment Research upgraded Align Technology from a “hold” rating to a “buy” rating and set a $227.00 price objective on the stock in a research report on Monday, October 30th. Eleven research analysts have rated the stock with a buy rating, Align Technology presently has a consensus rating of “Buy” and a consensus price target of $222.82.
Align Technology (ALGN) traded up $0.38 during trading hours on Friday, reaching $254.76. The company’s stock had a trading volume of 285,873 shares, compared to its average volume of 1,002,325. Align Technology has a 12 month low of $88.56 and a 12 month high of $258.88. The stock has a market capitalization of $20,430.00, a P/E ratio of 75.26, a P/E/G ratio of 2.43 and a beta of 1.41.
Align Technology (NASDAQ:ALGN) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $1.01 EPS for the quarter, beating the Zacks’ consensus estimate of $0.82 by $0.19. Align Technology had a return on equity of 25.60% and a net margin of 19.98%. The company had revenue of $385.30 million for the quarter, compared to the consensus estimate of $359.80 million. During the same quarter in the previous year, the business earned $0.63 earnings per share. The company’s revenue for the quarter was up 38.3% on a year-over-year basis. research analysts anticipate that Align Technology will post 3.62 earnings per share for the current fiscal year.
In related news, CMO Raphael Pascaud sold 5,400 shares of the business’s stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $241.88, for a total value of $1,306,152.00. Following the sale, the chief marketing officer now owns 22,228 shares in the company, valued at approximately $5,376,508.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Julie Tay sold 3,500 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $253.00, for a total value of $885,500.00. Following the completion of the sale, the vice president now owns 12,213 shares in the company, valued at approximately $3,089,889. The disclosure for this sale can be found here. Insiders sold 16,600 shares of company stock worth $4,031,567 in the last 90 days. Company insiders own 1.60% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/11/24/align-technology-algn-receiving-somewhat-favorable-news-coverage-study-shows.html.
Align Technology Company Profile
Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.
Receive News & Stock Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related stocks with our FREE daily email newsletter.